MedTrace Logo

Dostarlimab and Cobolimab in Advanced Cervical Cancer

NCT06238635 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2026-01-13

No results posted yet for this study

Summary

This research is being done to determine how effective dostarlimab in combination with cobolimab is in metastatic or recurrent cervical cancer.

Conditions

  • Cervical Cancer
  • Advanced Cervical Carcinoma
  • Metastatic Cervical Cancer
  • Metastatic Cervical Carcinoma
  • Recurrent Cervical Carcinoma

Interventions

DRUG

Dostarlimab

Humanized monoclonal antibody, 50mg/mL type 1 borosilicate clear glass vial, via intravenous infusion per protocol.

DRUG

Cobolimab

Humanized anti-TIM-3 monoclonal antibody, 20mg/mL single-use vial, via intravenous infusion per protocol.

Sponsors & Collaborators

Principal Investigators

  • Meghan Shea, MD · Beth Israel Deaconess Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-11
Primary Completion
2026-12-01
Completion
2027-07-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06238635 on ClinicalTrials.gov